(S)-ethyl 2-bromobutyrate | 130233-25-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (S)-ethyl 2-bromobutyrate
• 英文别名: ethyl (S)-2-bromobutyrate；(-)-Ethyl 2-bromobutyrate；ethyl (2S)-2-bromobutanoate
• CAS: 130233-25-9
• 化学式: C₆H₁₁BrO₂
• 分子量: 195.056
• InChiKey: XIMFCGSNSKXPBO-YFKPBYRVSA-N

物化性质

• 沸点：
  179.4±8.0 °C(Predicted)
• 密度：
  1.348±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-氯苯硫酚 、 (S)-ethyl 2-bromobutyrate 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 2.0h， 以80%的产率得到(R)-2-(4-Chloro-phenylsulfanyl)-butyric acid ethyl ester
  参考文献：
  名称：

  Ferorelli; Loiodice; Tortorella, Il Farmaco, 1997, vol. 52, # 6-7, p. 367 - 374

  摘要：

  DOI：
• 作为产物：
  描述：

  乙醇 、 S-2-溴丁酸 在 硫酸 作用下， 以80%的产率得到(S)-ethyl 2-bromobutyrate
  参考文献：
  名称：

  Ferorelli; Loiodice; Tortorella, Il Farmaco, 1997, vol. 52, # 6-7, p. 367 - 374

  摘要：

  DOI：

文献信息

• Enantioselectivity of Haloalkane Dehalogenases and its Modulation by Surface Loop Engineering
  作者：Zbynek Prokop、Yukari Sato、Jan Brezovsky、Tomas Mozga、Radka Chaloupkova、Tana Koudelakova、Petr Jerabek、Veronika Stepankova、Ryo Natsume、Jan G. E. van Leeuwen、Dick B. Janssen、Jan Florian、Yuji Nagata、Toshiya Senda、Jiri Damborsky

  DOI：10.1002/anie.201001753

  日期：2010.8.16

  In the loop: Engineering of the surface loop in haloalkane dehalogenases affects their enantiodiscrimination behavior. The temperature dependence of the enantioselectivity (lnE versus 1/T) of β‐bromoalkanes by haloalkane dehalogenases is reversed (red data points) by deletion of the surface loop; the selectivity switches back when an additional single‐point mutation is made. This behavior is not observed

  在回路中：卤代烷脱卤酶表面回路的工程设计会影响其对映异构行为。卤代烷脱卤酶对β-溴代烷烃的对映选择性（ln E对1 / T）的温度依赖性通过消除表面环而被逆转（红色数据点）。当进行其他单点突变时，选择性会切换回去。对于α-溴代酸酯未观察到此行为。
• GC Separation of Enantiomers of Alkyl Esters of 2-Bromo Substituted Carboxylic Acids Enantiomers on 6-TBDMS-2,3-di-alkyl- β- and γ-Cyclodextrin Stationary Phases
  作者：Ivan Špánik、Darina Kačeriaková、Jan Krupčík、Daniel Wayne Armstrong

  DOI：10.1002/chir.22310

  日期：2014.6

  The gas chromatographic separation of enantiomers of 2‐Br carboxylic acid derivatives was studied on four different 6‐TBDMS‐2,3‐di‐O‐alkyl‐ β‐ and ‐γ‐CD stationary phases. The differences in thermodynamic data ΔH and –ΔS} for the 15 structurally related racemates were evaluated. The influence of structure differences in the alkyl substituents covalently attached to the stereogenic carbon atom, as

  在4种不同的6-TBDMS-2,3-di-O-烷基-β-和γ-CD固定相上研究了2-Br羧酸衍生物对映体的气相色谱分离。热力学数据的差异 ΔH和–ΔS}对15个与结构相关的外消旋体进行了评估。详细研究了共价连接到立体碳原子上的烷基取代基以及同源分析物的酯基中结构差异的影响，以及改性β-和γ-环糊精衍生物的选择性。环糊精空腔的大小，以及6-TBDMS-β-CD的2和3位的烷基取代基的延伸，也影响了它们的选择性。对映体分离的质量主要受分子酯基团的烷基链影响，这似乎与所用的CD固定相无关。在某些情况下，分离是由于外部吸附而不是与手性选择剂形成包合物而发生的。手性26：279–285，2014。©2014 Wiley Periodicals，Inc.
• Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof
  申请人：Murata Masakazu

  公开号：US20100286210A1

  公开（公告）日：2010-11-11

  An object of the present invention is to provide novel carbazole derivatives, solvates thereof, or pharmaceutically acceptable salts thereof having an excellent adipose tissue weight reducing effect, hypoglycemic effect, and hypolipidemic effect, which are useful as a preventive and/or therapeutic agent for fatty liver, obesity, lipid metabolism abnormality, visceral adiposity, diabetes, hyperlipemia, impaired glucose tolerance, hypertension, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and the like. The above-mentioned object can be achieved by carbazole derivatives, solvates thereof, or pharmaceutically acceptable salts thereof, wherein the carbazole derivatives are represented by the following general formula (I): (In the formula (I), the ring A represents phenyl group or the like; X represents —O— or the like; Y represents ═N— or the like; a and b represent methylene group or the like; both V and Z represent —O— or the like; W represents a C 1 -C 10 alkylene group whose 1 or 2 hydrogen atoms may be substituted by a phenyl group or a C 1 -C 6 alkyl group; 1,2-phenylene group; 1,3-cyclohexyl group; or the like; R 1 represents methyl group or the like; R 2 represents methoxy group or the like; and R 3 represents carboxy group or the like.)

  本发明的目的是提供新型的咔唑衍生物、其溶剂化物或药学上可接受的盐，具有优异的减轻脂肪组织重量、降血糖和降血脂作用，可用作预防和/或治疗脂肪肝、肥胖症、脂质代谢异常、内脏脂肪、糖尿病、高脂血症、糖耐量受损、高血压、非酒精性脂肪肝病、非酒精性脂肪性肝炎等的药物。上述目的可以通过咔唑衍生物、其溶剂化物或药学上可接受的盐来实现，其中咔唑衍生物由下式(I)表示：（在式(I)中，环A表示苯基或类似物；X表示-O-或类似物；Y表示═N-或类似物；a和b表示甲基烷基或类似物；V和Z都表示-O-或类似物；W表示C1-C10烷基，其1或2个氢原子可被苯基或C1-C6烷基取代；1,2-苯基烷基；1,3-环己基烷基或类似物；R1表示甲基或类似物；R2表示甲氧基或类似物；R3表示羧基或类似物。）
• Enantiodiscrimination of racemic electrophiles by diketopiperazine enolates: asymmetric synthesis of methyl 2-amino-3-aryl-butanoates and 3-methyl-aspartates
  作者：Steven D. Bull、Stephen G. Davies、Simon W. Epstein、A. Christopher Garner、Nadeam Mujtaba、Paul M. Roberts、Edward D. Savory、Andrew D. Smith、Juan A. Tamayo、David J. Watkin

  DOI：10.1016/j.tet.2006.05.033

  日期：2006.8

  Enolates of (S)-N,N'-bis-(p-methoxybenzyl)-3-iso-propylpiperazine-2,5-dione exhibit high levels of enantiodiscrimination in alkylations with (RS)-1-aryl-1-bromoethanes and (RS)-2-bromoesters, affording substituted diketopiperazines containing two new stereogenic centres in high de. Deprotection and hydrolysis of the resultant substituted diketopiperazines provides a route to the asymmetric synthesis of homochiral methyl 2-amino-3-aryl-butanoates and 3-methyl-aspartates in high de and ee. (c) 2006 Elsevier Ltd. All rights reserved.
• CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：ZERIA PHARMACEUTICAL CO., LTD.

  公开号：EP1852433B1

  公开（公告）日：2011-11-23